Gilead’s remdesivir fails to show benefit in European trial

 Two promising drugs for COVID-19 fail to deliver

Two drugs that looked like promising treatments for COVID-19 in preliminary studies – remdesivir for hospitalized patients and camostat for patients who are not seriously ill – failed to show a benefit in those groups in randomized controlled trials, researchers reported in two separate papers.

In five European countries, researchers studied 843 COVID-19 patients who were hospitalized between March 2020 and January 2021 and who needed oxygen or machines to help with breathing. Two week after patients had received either Gilead Sciences’ antiviral remdesivir – sold as Veklury – plus standard of care or standard of care alone for up to 10 days, there was no difference between the groups in signs of improvement, investigators reported on Thursday https://www.medrxiv.org/content/10.1101/2022.03.30.22273206v1.

In Japan between November 2020 and March 2021, researchers randomly assigned 155 patients with mild or moderate COVID-19 to receive the pancreatitis drug camostat mesylate from Ono Pharmaceutical Co or a placebo for up to 14 days. Camostat blocks an enzyme that helps some versions of the coronavirus infect cells – including the variants circulating at the time of the study – but did not help patients get rid of the virus in their airways any faster than placebo, the Japanese researchers reported on Saturday https://www.medrxiv.org/content/10.1101/2022.03.27.22271988v1. They said the results “highlight… the necessity of conducting well-designed studies to confirm whether preclinical findings translate into meaningful clinical efficacy.” Both studies were posted on medRxiv ahead of peer review.

https://wtvbam.com/2022/04/04/gileads-remdesivir-fails-to-show-benefit-in-european-trial-no-fetus-risk-seen-with-first-trimester-vaccination/